I respectfully disagree. I think there are competitors coming (from memory) so Acadia might not be inclined to let them enter the market.
If you already are a name in the community, then providing families with a much better and more tolerable drug would be better than letting a competitor enter the market and steal a share.
If patients transition from Trof to 2591 and they get better outcomes with less side effects, you are less likely to transition to a competitor - at least that would be my take.
Pipeline-in-a-drug, page-180
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |